We are live on ! Find out more
ALXN

Alexion Pharmaceuticals
ALXN

Delisted

ALXN was delisted on the 20th of July, 2021.

Back to rankings

1 hedge funds and large institutions have $13K invested in Alexion Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 1 → 1 (0)

19% less capital invested

Capital invested by funds: $16K → $13K (-$3K)

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter

ALXN Hedge Fund Activity: Q4 2022 in Review

1 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q4 2022, worth a combined $13K — down 19% from $16K a quarter earlier.

Fund positioning in ALXN was balanced in Q4 2022: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 1 institutional investor held Alexion Pharmaceuticals (ALXN) as of Q4 2022, unchanged from Q3 2022.
  • Funds reported $13K of Alexion Pharmaceuticals stock for Q4 2022, down 19% quarter-over-quarter.
  • 0 funds opened new Alexion Pharmaceuticals positions in Q4 2022 and 0 closed out.

Based on aggregated 13F filings for Q4 2022.